proteolysis-targeting chimeras

Show results for

Unknown (470)
Proteomics (87)
Genomics (59)
Transcriptomics (26)
Other (2)
Metabolomics (1)

Organisms

Andropogon gerardi (54)
Bacteria (54)
Bartonella quintana JK 31 (54)
Canis lupus familiaris (54)
Clavibacter nebraskensis NCPPB 2581 (54)
Cnidaria (54)
Ensifer adhaerens (54)
Human alphaherpesvirus 1 strain 17 (54)
Human alphaherpesvirus 1 strain KOS (54)
Human betaherpesvirus 5 (54)
Human herpesvirus 2 strain 186 (54)
Mesocricetus auratus (54)
Miscanthus x giganteus (54)
Mus musculus (54)
Panicum virgatum (54)
Platyhelminthes (54)
Pseudomonas aeruginosa PA103 (54)
Rabies virus Nishigahara RCEH (54)
Rattus norvegicus (54)
Rattus rattus (54)
Rhodococcus jostii RHA1 (54)
Rhodopseudomonas palustris (54)
Shigella (54)
Sorghastrum nutans (54)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (54)
Streptococcus pneumoniae (54)
Streptomyces coelicolor A3(2) (54)
Synechocystis sp. PCC 6803 (54)
Homo sapiens (43)
Mus musculus (14)

Organisms

Homo sapiens (22)
Mus musculus (20)
unidentified (1)

Repository

pride (54)
ENA (49)
geo (36)
MassIVE (15)
iProX (13)
jPOST (5)
biostudies-arrayexpress (1)
EGA (1)
MetaboLights (1)

Tissue

Cell culture (24)
Kidney cell (6)
Epithelial cell (5)
Permanent cell line cell (4)
Blood cell (3)
Cell suspension culture (3)
Early embryonic cell (2)
Fibroblast (2)
Liver (2)
Lung (2)
A549-CR cell (1)
Blood (1)
Bone marrow (1)
Cervix epithelium (1)
HL-60 cell (1)
HeLa cell (1)
Lymph node (1)
Macrophage (1)
Malignant cell (1)
Myeloid cell (1)
Spleen (1)
T cell (1)

Disease

Acute leukemia (7)
Breast cancer (2)
Multiple myeloma (2)
Cervical adenocarcinoma (1)
Cervix carcinoma (1)
Colon cancer (1)
Disease free (1)
Lung adenocarcinoma (1)
Lymphoma (1)
Malignant neoplasm of ovary (1)
Parkinson's disease (1)

Technology Type

Mass Spectrometry (54)
Bottom-up proteomics (25)
Shotgun proteomics (21)
Data-dependent acquisition (9)
Data-independent acquisition (9)
Gel-based experiment (3)
SWATH MS (2)
Mass spectrometry (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)
DiaPASEF (1)
SRM/MRM (1)
Top-down proteomics (1)

Instrument Platform

Orbitrap Exploris 480 (5)
Orbitrap Fusion Lumos (5)
Orbitrap Eclipse (4)
Agilent TapeStation (1)
Element AVITI (1)
None (1)
Bruker Daltonics instrument model (1)
Q Exactive HF-X (1)
QTRAP 5500 (1)
TimsTOF fleX (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2025 (38)
2026 (30)
2023 (22)
2022 (13)
2024 (12)
2021 (4)
2020 (2)
2018 (2)
2019 (1)

CHEBI ID

CHEBI:189652 (1)

Metabolite Name

Mz1 (1)

First Public Date

2023 (16)
2026 (15)
2025 (7)
2024 (4)
2022 (3)
2021 (3)
2019 (1)

Study type

RNA-seq of coding RNA (1)

Release Date

2025 (90)
2024 (83)
2022 (75)
2023 (74)
2021 (64)
2020 (31)
2026 (23)
2019 (15)
2018 (7)
2017 (4)
2016 (1)
2015 (1)
2013 (1)
2011 (1)
2010 (1)

Lab affiliation

Principal Investigator Centre for Targeted Protein Degradation, School of Life Sciences (4)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (3)
Department of Structural Biology and Developmental Neurobiology, Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA (3)
Cancer Research UK Scotland Institute (Formerly the Cancer Research UK Beatson Institute) Garscube Estate Switchback Road Bearsden Glasgow, G61 1BD (2)
LMU Munich, Department of Chemistry (2)
Principal Investigator Centre for Targeted Protein Degradation (2)
Principal Investigator • Centre for Targeted Protein Degradation (2)
University of Dundee, Scool of Life Sciences, Department of Molecular, Cellular andDevelopmental biology (2)
Amgen (1)
Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States (1)
Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States (1)
Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA (1)
Department of Health Sciences and Technology (D-HEST) Institute Neurosciences, ETH Zurich (1)
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA (1)
Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 2, Ireland. Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2, Ireland. (1)
Department of Radiology Perelman School of Medicine at the University of Pennsylvania (1)
Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA Department of Molecular Machines and Signaling, Max Planck Institute of Biochemistry, Martinsried, Germany (1)
Facutly of Science, University of Geneva (1)
FingerPrints Proteomics Facility, School of Life Sciences, University of Dundee, Dundee, UK (1)
Head Proteomics Group, Leiden University Medical Center, Center for Proteomics and Metabolomics, PO Box 9600, Postal zone P1-Q, 2300 RC Leiden, The Netherlands (1)
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical School (1)
Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany (1)
Institute of Pharmacology and Toxicology RWTH Aachen University Wendlingweg 2 52074 Aachen, Germany (1)
MRC PPU, School of Life Sciences University of Dundee (1)
Mass Spectrometry & Proteomics Core Facility (MSPCF) Institute for Research in Biomedicine (IRB Barcelona) Barcelona Institute of Science and Technology (BIST) C/ Baldiri Reixac, 10-12 08028 Barcelona - Spain. (1)
Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom (1)
Medicinal Chemistry, Monash Institute of Pharmaceutica Science, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia (1)
National Center for Advancing Translational Sciences (NCATS) NIH (1)
Oerthbio (1)
Pfizer, INC. (1)

Previous page
1 / 65
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 65
Next page

Sort by:

Relevance

Page size

Structure-guided development of chemically tailored peptide binders of RNF43/ZNRF3 to enable versatile design of membrane protein-targeting PROTACs

Targeted membrane protein degradation using cell surface E3 ligases RNF43/ZNRF3 via proteolysis targeting chimeras (PROTACs) represents an effective strategy for treating membrane drug targets that cannot be fully inhibited using traditional inhibitors. Several ingenious chimeras have been developed...

ORGANISM(S): Homo Sapiens

2025-03-04 | PXD061425 |

Global proteomics and metabolic data for CD36-mediated endocytosis of proteolysis-targeting chimeras

Global proteomics and metabolic data for CD36-mediated endocytosis of proteolysis-targeting chimeras are deposited here.

ORGANISM(S): Homo Sapiens (human)

2025-04-10 | PXD062797 | JPOST Repository

Global proteomics and metabolic data for CD36-mediated endocytosis of proteolysis-targeting chimeras

Global proteomics and metabolic data for CD36-mediated endocytosis of proteolysis-targeting chimeras has been deposited here.

ORGANISM(S): Homo Sapiens (human)

2025-04-09 | PXD062747 | JPOST Repository

Proteolysis targeting chimeras (PROTACs) in cancer therapy.

Not available

S-EPMC7493969 | biostudies-literature

Computer aided drug design in the development of proteolysis targeting chimeras.

Not available

S-EPMC10030821 | biostudies-literature

Proteolysis-targeting chimeras with reduced off-targets.

Not available

S-EPMC10913580 | biostudies-literature

Repurposing E3 ubiquitin ligases as cell surface protein degraders using Proteolysis Targeting Antibodies

The majority of current therapeutics targeting plasma membrane receptors function by antagonizing ligand binding or enzymatic activities. Typical mammalian proteins, however, consist of multiple domains executing discrete but coordinated activities, and saturating inhibition of one functional domain...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

2022-05-25 | MSV000089542 | MassIVE

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras.

Not available

S-EPMC5200928 | biostudies-literature

The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells

Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce selective protein degradation by linking an E3 ubiquitin ligase enzyme to a target protein. This approach allows scope for targeting “undruggable” proteins and several PROTACs have reached the stage of clinical candidate...

2025-07-17 | MTBLS11394 | MetaboLights

The clinical advances of proteolysis targeting chimeras in oncology.

Not available

S-EPMC9400722 | biostudies-literature

Previous page
1 / 65
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 65
Next page

Sort by:

Relevance

Page size

645 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Study type

Release Date

Lab affiliation

Tags

OmicsDI is part of the ELIXIR infrastructure

Tweets